Profil
Stacey L.
Jurchison worked as a Communications Director & Head-Investor Relations at PharmAthene, Inc. from 2012 to 2014.
She also worked as a Senior Director-Investor Relations at Aptevo Therapeutics, Inc. and Altimmune, Inc. Additionally, she worked as an Executive Director-Corporate Affairs at Prelude Therapeutics, Inc. from 2019 to 2022.
Furthermore, she worked as an Investor Relations Contact & Head-Communications at Rexahn Pharmaceuticals, Inc.
Ehemalige bekannte Positionen von Stacey L. Jurchison
| Unternehmen | Position | Ende |
|---|---|---|
| PRELUDE THERAPEUTICS INCORPORATED | Investor Relations Contact | - |
| ALTIMMUNE, INC. | Investor Relations Contact | - |
| REXAHN PHARMACEUTICALS, INC. | Investor Relations Contact | - |
| APTEVO THERAPEUTICS INC. | Investor Relations Contact | - |
PharmAthene, Inc.
 PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Investor Relations Contact | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| APTEVO THERAPEUTICS INC. | Health Technology |
| PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
| ALTIMMUNE, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Rexahn Pharmaceuticals, Inc.
 Rexahn Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of oncology therapeutics. Its drug candidates include the following: RX-31171 for pancreatic, bladder, colon, and lung cancer; and RX-5902 for metastatic triple negative breast cancer. The company was founded by Chang Ho Ahn on March 19, 2001 and is headquartered in Rockville, MD. | Health Technology |
PharmAthene, Inc.
PharmAthene, Inc. BiotechnologyHealth Technology PharmAthene, Inc. engages in the development and commercialization of medical countermeasures against biological and chemical threats. Its development portfolio includes a next generation anthrax vaccine that is intended to provide protection while having dosage and storage requirements. The company was founded in March 2001 and is headquartered in Annapolis, MD. | Health Technology |
